Tak Paul Peter Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
3
Insider Buys Sum
$230,020.20
Insider Sells Quantity
7
Insider Sells Sum
$1.05M

Insider Activity of Tak Paul Peter

According to the SEC Form 4 filings, Tak Paul Peter, being in a position of

  1. Chief Executive Officer at Candel Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 280245 shares for $3.16M,
    over all time since 2021-07-29, has bought 40985 shares for $230,020, and sold 440961 share for $4.21M.

Biography of Tak Paul Peter

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$3,160,7832100

Comparison of Insiders on Amount of Buys and Sells

2026-09-11SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
59,379
0.0804%
$10.46$620,891-6.88%
2026-09-10SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
220,866
0.306%
$11.50$2.54M-13.11%
2025-03-19SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
400
0.0009%
$9.00$3,601-38.76%
2025-03-18SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
25,772
0.0576%
$8.77$226,023-38.21%
2025-01-15SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
21,704
0.0476%
$7.22$156,811-30.13%
2025-01-08SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
21,172
0.0454%
$8.22$173,996-36.03%
2024-11-29SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
48,847
0.1456%
$4.56$222,527+19.96%
2024-07-17SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
22,528
0.0746%
$6.47$145,815-9.67%
2024-07-11SaleCandel Therapeutics, Inc.
CADL
Chief Executive Officer
20,293
0.0713%
$5.97$121,218+0.42%
2022-12-09PurchaseCandel Therapeutics, Inc.
CADL
Chief Executive Officer
12,935
0.0411%
$1.92$24,835-35.41%
2022-12-08PurchaseCandel Therapeutics, Inc.
CADL
Chief Executive Officer
3,050
0.0094%
$1.70$5,185-28.95%
2021-07-29PurchaseCandel Therapeutics, Inc.
CADL
Chief Executive Officer
25,000
0.1175%
$8.00$200,000-24.18%
Total: 12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.